Oakworth Capital, Inc. Repligen Corp Transaction History
Oakworth Capital, Inc.
- $1.44 Billion
- Q3 2024
A detailed history of Oakworth Capital, Inc. transactions in Repligen Corp stock. As of the latest transaction made, Oakworth Capital, Inc. holds 250 shares of RGEN stock, worth $35,762. This represents 0.0% of its overall portfolio holdings.
Number of Shares
250
Previous 250
-0.0%
Holding current value
$35,762
Previous $31,000
19.35%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding RGEN
# of Institutions
488Shares Held
54.2MCall Options Held
341KPut Options Held
235K-
Black Rock Inc. New York, NY7.57MShares$1.08 Billion0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.39MShares$914 Million0.11% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.04MShares$722 Million0.01% of portfolio
-
State Street Corp Boston, MA1.62MShares$232 Million0.01% of portfolio
-
Champlain Investment Partners, LLC Burlington, VT1.42MShares$203 Million1.34% of portfolio
About REPLIGEN CORP
- Ticker RGEN
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 55,491,200
- Market Cap $7.94B
- Description
- Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....